The abstract is read at the publisher; the summary is JClub's.
Modified immune cell therapy using mitomycin C in NZB/W F1 mice reduces lupus nephritis progression, lowering protein excretion and serum creatinine versus controls at standard dose.
- Why it matters: The mechanism and optimal dosing for mitomycin C–treated immune cells in lupus nephritis are unclear, limiting translation beyond prior autoimmunity and transplant studies.
- What they did: Splenocytes from syngeneic NZB/W F1 donors were challenged with mitomycin C and transferred into BWF1 recipients at 25 weeks, then assessed for five weeks; in vitro, autologous macrophages cleared MIC from 25 patients with lupus and matched healthy individuals.
- The result: MIC-treated mice showed altered kidney-proximal tertiary lymphoid structures (including germinal center disintegration) and increased CD19+CD5+CD1d high regulatory-like B cells, while higher-dose MIC gave no added clinical benefit and patient macrophages efficiently cleared MIC in vitro.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.